CA3219372A1 - Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy - Google Patents

Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy

Info

Publication number
CA3219372A1
CA3219372A1 CA3219372A CA3219372A CA3219372A1 CA 3219372 A1 CA3219372 A1 CA 3219372A1 CA 3219372 A CA3219372 A CA 3219372A CA 3219372 A CA3219372 A CA 3219372A CA 3219372 A1 CA3219372 A1 CA 3219372A1
Authority
CA
Canada
Prior art keywords
antibody
cd16a
combination
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3219372A
Other languages
English (en)
French (fr)
Inventor
Martin Treder
Uwe Reusch
Jens-Peter Marschner
Stefan Knackmuss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15166303.6A external-priority patent/EP3091031A1/en
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of CA3219372A1 publication Critical patent/CA3219372A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3219372A 2015-05-04 2016-05-04 Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy Pending CA3219372A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15166303.6 2015-05-04
EP15166303.6A EP3091031A1 (en) 2015-05-04 2015-05-04 Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
EP16152650.4 2016-01-25
EP16152650 2016-01-25
CA2983706A CA2983706C (en) 2015-05-04 2016-05-04 Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2983706A Division CA2983706C (en) 2015-05-04 2016-05-04 Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy

Publications (1)

Publication Number Publication Date
CA3219372A1 true CA3219372A1 (en) 2016-11-10

Family

ID=56026814

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3219372A Pending CA3219372A1 (en) 2015-05-04 2016-05-04 Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy
CA2983706A Active CA2983706C (en) 2015-05-04 2016-05-04 Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2983706A Active CA2983706C (en) 2015-05-04 2016-05-04 Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy

Country Status (20)

Country Link
US (1) US11167029B2 (https=)
EP (1) EP3292153B1 (https=)
JP (1) JP6609784B2 (https=)
CN (1) CN107847587B (https=)
AU (1) AU2016257334B2 (https=)
BR (1) BR112017023579A2 (https=)
CA (2) CA3219372A1 (https=)
CY (1) CY1122283T1 (https=)
DK (1) DK3292153T3 (https=)
ES (1) ES2754557T3 (https=)
HR (1) HRP20191933T1 (https=)
HU (1) HUE045866T2 (https=)
LT (1) LT3292153T (https=)
PL (1) PL3292153T3 (https=)
PT (1) PT3292153T (https=)
RS (1) RS59489B1 (https=)
RU (1) RU2761352C2 (https=)
SI (1) SI3292153T1 (https=)
SM (1) SMT201900598T1 (https=)
WO (1) WO2016177846A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018226526B2 (en) 2017-02-28 2025-03-13 Affimed Gmbh Combination of an anti-CD16A antibody with a cytokine
WO2018158349A1 (en) 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement
CN109706164A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用
CN109706163A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用
BR112020018492A2 (pt) 2018-03-14 2020-12-29 Affimed Gmbh Proteína de ligação ao antígeno egfr/cd16 biespecífica
CA3095373A1 (en) * 2018-04-13 2019-10-17 Affimed Gmbh Nk cell engaging antibody fusion constructs
HRP20240821T1 (hr) * 2018-08-27 2024-09-27 Affimed Gmbh Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt
CN109402168A (zh) * 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
JP2022536684A (ja) * 2019-06-11 2022-08-18 マイエロイド・セラピューティクス，インコーポレーテッド マクロファージ特異的エンゲージャー組成物およびその使用方法
AU2020414409A1 (en) * 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
JP2024503933A (ja) * 2021-01-27 2024-01-29 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド Ｃｄ１６ａに対する単一ドメイン抗体およびその使用
WO2023274183A1 (zh) 2021-06-29 2023-01-05 江苏先声药业有限公司 Cd16抗体及其应用
EP4413039A1 (en) 2021-10-08 2024-08-14 Genmab A/S Antibodies binding to cd30 and cd3
CN118613271A (zh) * 2021-11-04 2024-09-06 埃迪瓦生物治疗公司 用nk细胞和多特异性接合子治疗癌症
WO2023080895A1 (en) * 2021-11-04 2023-05-11 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and multispecific engagers
CN116059348A (zh) * 2022-09-16 2023-05-05 四川大学华西医院 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用
WO2024114676A1 (zh) 2022-11-29 2024-06-06 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途
AR132290A1 (es) 2023-04-05 2025-06-11 Genmab As Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3
CN117442721B (zh) * 2023-12-20 2024-03-15 苏州艾凯利元生物科技有限公司 一种包括nk细胞和nk细胞接合器分子的组合物
CN118791616A (zh) * 2024-09-14 2024-10-18 苏州为度生物技术有限公司天津分公司 一种抗人cd16工程抗体及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
CA2611861C (en) * 2005-06-08 2017-11-28 The Brigham And Women's Hospital, Inc. Methods and compositions for the treatment of persistent infections
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP3183269A2 (en) * 2014-08-22 2017-06-28 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody

Also Published As

Publication number Publication date
JP2018514576A (ja) 2018-06-07
PT3292153T (pt) 2019-11-05
CN107847587A (zh) 2018-03-27
RU2761352C2 (ru) 2021-12-07
RS59489B1 (sr) 2019-12-31
CN107847587B (zh) 2020-10-09
LT3292153T (lt) 2019-11-11
US11167029B2 (en) 2021-11-09
JP6609784B2 (ja) 2019-11-27
AU2016257334B2 (en) 2021-08-12
BR112017023579A2 (pt) 2018-07-24
CY1122283T1 (el) 2020-11-25
ES2754557T3 (es) 2020-04-20
PL3292153T3 (pl) 2020-02-28
HUE045866T2 (hu) 2020-01-28
CA2983706A1 (en) 2016-11-10
WO2016177846A1 (en) 2016-11-10
AU2016257334A1 (en) 2017-11-09
SI3292153T1 (sl) 2020-01-31
EP3292153A1 (en) 2018-03-14
US20180085456A1 (en) 2018-03-29
RU2017137251A3 (https=) 2019-10-10
HK1253022A1 (zh) 2019-06-06
HRP20191933T1 (hr) 2020-01-10
DK3292153T3 (da) 2019-10-21
EP3292153B1 (en) 2019-07-31
RU2017137251A (ru) 2019-06-04
SMT201900598T1 (it) 2020-01-14
CA2983706C (en) 2024-01-02

Similar Documents

Publication Publication Date Title
CA2983706C (en) Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy
US20250163152A1 (en) Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
US20260001964A1 (en) Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof
AU2014351308B2 (en) Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
CN110511278B (zh) 抗b7-h6抗体、融合蛋白及其使用方法
US20170015758A1 (en) Compositions And Methods For Modulating And Redirecting Immune Responses
KR20220005627A (ko) 면역반응의 조절을 위한 방법 및 항체
WO2015198312A1 (en) Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
KR20200074214A (ko) 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체
TW202104263A (zh) 雙特異性CD123xCD3雙抗體在血液系統惡性腫瘤治療中的給藥方案
EP3091031A1 (en) Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
Baeuerle Development of T‐Cell‐Engaging Bispecific Antibody Blinatumomab (Blincyto®) for Treatment of B‐Cell Malignancies
HK1253022B (zh) Cd30×cd16抗体与pd-1拮抗剂的联合药物
RU2773655C2 (ru) Комбинация, содержащая перенаправляющие т-клетки многофункциональные антитела и модуляторы контрольных точек, и ее применения
HK40056381A (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231109

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250109

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250424

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250424

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250508

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250509

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250509

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250509

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20260413

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260415